Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Citi
US Department of Justice
Baxter
Julphar
US Army
UBS
Healthtrust
Accenture

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,399,496

« Back to Dashboard

Which drugs does patent 8,399,496 protect, and when does it expire?

Patent 8,399,496 protects CAYSTON and is included in one NDA.

This patent has thirty-nine patent family members in eighteen countries.
Summary for Patent: 8,399,496
Title:Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.
Inventor(s): Montgomery; Alan Bruce (Seattle, WA), Keller; Manfred (Munchen, DE), Lintz; Frank-Christophe (Starnberg, DE)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:12/229,425
Patent Claim Types:
see list of patent claims
Composition; Use; Formulation;

Drugs Protected by US Patent 8,399,496

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gilead CAYSTON aztreonam FOR SOLUTION;INHALATION 050814-001 Feb 22, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,399,496

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,208,141 Inhalable aztreonam aerosol for treatment and prevention of pulmonary bacterial infections ➤ Sign Up
7,214,364 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections ➤ Sign Up
7,427,633 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections ➤ Sign Up
6,660,249 Inhalable dry powder aztreonam for treatment and prevention of pulmonary bacterial infections ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Covington
Teva
Fish and Richardson
Baxter
US Army
Chinese Patent Office
Colorcon
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.